secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001171843-24-006847
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics appoints Barry Shin as CFO; Neil Lerner as PAO
-------------------------------------------------------------------

- Barry Shin named CFO effective Dec 9, 2024; base salary $475K, target bonus 45%, sign-on $50K, and equity grants of 800K shares total.
- Neil Lerner appointed principal accounting officer; he was VP of Finance since November 2020.
- Shin replaces Thomas Schuetz as principal financial officer; Schuetz remains CEO.
- Press release highlights 2025 catalysts: topline data for CTX-009 expected in Q1 2025.
- Shin previously served as CFO/COO at Trevena and held investment banking roles at Mizuho, Guggenheim, and Piper Sandler.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324006847/0001171843-24-006847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324006847/f8k_121024.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer